EGFR and ovarian carcinoma: As specific TKIs are usually applied over the long term for oncological therapy, the present study aimed to examine the consequences of long-term treatment of anti-EGFR TKIs on ovarian cancer cells displaying intrinsic resistance to anti-EGFR antibodies.